Menu Menu
We support multiple therapeutic areas
theraputic-1

 

Over 30 million adults suffer from Cardiovascular Disease in India. Due to changes in lifestyle and economic conditions, the prevalence of risk factors for coronary heart disease has rapidly increased. The overall incidence of heart disease has doubled in India over the last 20 years, with the trend expecting to continue.

According to a survey by World Health Organization (WHO) ischemic heart diseases accounted for 1215.4 thousand deaths in India in the year 2012, thereby making it the leading cause of death in India. The data recorded in 2010 stated that non-communicable diseases accounted for nearly 53% deaths in India, of which nearly 12.72% are due to CVD. Statistics show that non-communicable diseases account for 53% of deaths in India, of which 25% are due to CVD.

Our access to the most prominent Cardiology sites and Investigators ensures a large and diverse patient pool, and leading lines of medical treatment. Historically, access to such a large group of patients from some of the country’s leading cardiology researchers has resulted in achieving enrollment targets on time or ahead of schedule – though speed is never a substitute for our focus on quality and ethics. We ensure that clinical trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download:Cardiology Brochure 

Dermatology

The science of dermatology in India has evolved over the last 20 years from a specialty practice to a mainstream commercial practice with over 10,000 practitioners throughout the country. India, with a population of over 1.25 billion, is an ideal location for conducting clinical research in dermatology. One of every twenty people and 20-30% of cases in pediatric practice have dermatological issues. Many patients are treatment naïve and non-transient.

India therefore is an ideal location for conducting clinical research in dermatology. Most prevalent skin diseases include pediculosis, tinea, vitiligo, pityriasis versicolor, pityriasis, alba, dermatitis, urticaria, impetigo, scabies and boils.

Fungal infections of the skin are seen in 28% patients with a higher prevalence among males. Tinea corporis accounts for 78% of the superficial fungal infections. The prevalence of pediculosis among school children varies from 17% in one study, to 56% in another. Eczema and skin allergies account for nearly 30% of the cases as accounted by pediatric dermatologists in India. Acne has affected nearly 51% of boys and 38% of girls in the age group 12-17 years. In 2013, about 35% of the young girls in India were confirmed polycystic ovary disease (PCOD)

Excel Life Sciences (ELS) has significant experience in running and supporting clinical trials for dermatology in India. In fact, ELS has one of the largest networks of investigative sites and investigators in India, including some of the country’s leading Dermatology investigators and centers.

Using sophisticated databases of detailed site information, demographics and epidemiology data we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients. We have significant experience in the area of dermatology and we are confident that we can assist you with your next study.

We ensure that dermatological clinical trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download: Dermatology Brochure
Over 108 million people in India suffer from endocrine and metabolic disorders. Diabetes is the most prevalent disease in this therapeutic area with approximately 63 million cases in 2013. In 2011, nearly 983, 000 deaths were reported to be caused due to diabetes, thereby making it the largest contributor to mortality. Seventy eight thousand children are reported to develop type1 diabetes, every year.

As diabetes becomes a potential epidemic in India, this figure is likely to rise to 80 million by 2025 and by 2030, it is expected to cross the 100 million mark (one in every 10 adults), near twice as many as expected in China.

Our Principal Investigators see 400 - 500 new cases per month, and approximately 2000 recurrent cases per month. Some of their fields of expertise are diabetes, thyroid disorder, obesity and lipid disorders. Their research has been published in some of the country’s top medical journals including the National Medical Journal of India, Post Graduate Medical Journal and Journal of Association of Physicians of India (JAPI).

In other metabolic centric disease, 42 million people in India suffer from thyroid diseases. As to fertility, a 2013 World Bank estimate, since the year 2000, there has been a steady, 17% decline in fertility. Out of every 100 couples in India who visit the infertility clinics, the female is infertile in 50%, the male, in 40%.

We ensure that metabolic and endocrine clinical trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download: Endocrinology Brochure
The most common diseases seen under gastroenterology are hepatitis and cirrhosis of the liver. The most common cause of acute viral hepatitis in India, is hepatitis E virus (HEV). Hepatitis B virus (HBV) is the second most common, affecting over 40 million people. Nearly one million Indians are at risk for HBV and about 100,000 die from HBV infection every year. The population prevalence of hepatitis C virus (HCV) infection in India is 1%.

Inflammatory bowel disease (IBD) is now increasingly diagnosed in clinical practice. The incidence of UC in Asian countries ranges from 0.68 - 5.4 per 100,000 population, which is lower than the incidence rate of 6 per 100,000 recorded in India. The prevalence of UC is significant; in the range of 42-44 per 100,000 person-years.

In India, the males are about eighteen times more susceptible to peptic ulcer related mortality than females. Per the latest statistics available, nearly 200,000 people in India die due to terminal liver disease. Other diseases of the digestive system affecting the esophagus, stomach, intestines, liver and pancreas constitute a major public health problem in India. Other diseases seen under gastroenterology are cirrhosis of the liver, chronic cholecystitis, and cholelithiasis.

We have conducted a number of studies in the area of gastroenterology and we are confident that we can assist you with your next study. Excel Life Sciences (ELS) has developed one of the most experienced and sophisticated networks of gastroenterology investigators and investigative sites in India. Each has deep access to a large and diverse patient pool. Using our databases of detailed site information, demographics and epidemiology data we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients.

We ensure that gastroenterology clinical trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download: Gastroenterology Brochure
Globally, India has the third highest number of people living with HIV. In 2013, the estimated prevalence of HIV in India was 0.3% and there was an estimate of 130,000 AIDS-related deaths.

Between 2005 and 2013, the number of new HIV infections had declined by 19%, however, India still accounted for 38% of all new HIV infections in Asia. In 2013, more than 700,000 people in India were on antiretroviral therapy. This makes it the second highest number of people on HIV treatment in any single country next only to South Africa.

India accounted for 51% of all the AIDS-related deaths in Asia in 2013, which is more than three times the percentage for China. HIV spending is the third ranking specialty spending across oncology, autoimmune, I.D. and CNS, at $14.8B.

Tuberculosis. Every fifth new tuberculosis case in the world lives in the Indian subcontinent. It is estimated 40% of the population carries a form of the strain. A WHO report indicates India has the highest number of TB resistant strains in the world with India being the country harboring the highest number of TB cases in 2014, followed by Indonesia and China. Viral hepatitis. There are over 500 million people living with chronic hepatitis in the country, with viral hepatitis claims 250,000 lives in India every year.

Excel Life Sciences (ELS) has significant experience in running and supporting clinical trials for HIV and infectious diseases in India. In fact, ELS has one of the largest networks of investigative sites and investigators in India, including some of the country’s leading investigators and centers treating infectious diseases.. Many patients are treatment naïve and non-transient. These factors typically result in shortened enrollment times.

Our access to the most prominent Neuropsychiatry sites and Investigators ensures a large and diverse patient pool and leading lines of medical treatment. Their fields of expertise include the following anti retroviral treatments - NRTI + NNRTI and NRTI + PI. Many have been published in international medical journals and Indian journals including the Journal of Acquired Immune Deficiency Syndrome.

Using our internal databases and epidemiology intelligence we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients.

We ensure that infectious disease based clinical trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download:HIV_ID Brochure 
India’s growing incidence of Hypertensive and Diabetic patients contribute to a great prevalence of kidney related diseases. It is estimated that every 5th patient with high blood pressure and every 7th patient with diabetes, will develop Chronic Kidney Disease (CKD). Currently, the rate of Chronic Kidney Disease (CKD) in India is estimated at 0.2%. This translates into approximately 2,000,000 patients. In many cases, this progresses to Chronic Renal Failure (CRF), affecting over 200,000 patients each year. Other common kidney related disorders in India are Urolithiasis, Urinary Tract Infections, Glomerulopathies, and disorders regarding body fluids and electrolytes.

The growing incidence of hypertension and diabetes in India has also contributed significantly to the prevalence of kidney related diseases. Diabetes and hypertension account for 40-60% cases of chronic kidney disease (CKD). The increase in cases of diabetes and hypertension cases in urban India has resulted in an increase in the number of people suffering from kidney disease (nearly 17%). Out of this, nearly 6% have stage III kidney disease which needs medical attention. The yearly incidence of end stage renal disease (ESRD) in India is approximately 150–200 per million people.

We have conducted a number of studies in the area of nephrology and we are confident that we can assist you with your next study. Excel Life Sciences (ELS) has developed one of the most experienced and sophisticated networks of nephrology investigators and investigative sites in India. Each has deep access to a large and diverse patient pool and sees more than 100 new patients every month. Using our databases of detailed site information, demographics and epidemiology data we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients.

We ensure that nephrology clinical trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download: Nephrology Brochure
With its large and growing population, India has developed significant prevalence of neurological and psychiatric diseases and disorders. Statistics show that in India there are more than 10 million cases of neuropsychiatric conditions currently being treated. The World Health Organization (WHO) estimates that a minimum of 25 million people in India are in need of mental health services.

The rising rates of dementia, TBI and stroke will potentially add over 3.5 million people to the disabled population, annually. The condition with the greatest prevalence in India is Epilepsy. In addition there are approximately 10 million cases of other neuropsychiatric conditions including Stroke, TIA, Parkinson's Disease, Vascular Dementia, Alzheimer's Dementia, Migraine, Epilepsy, Cluster Headache, Neuropathies - Diabetic & Non diabetic, Brain tumors, Multiple Sclerosis, Meningitis, MDD, and Schizophrenia.

Dementia. The second contributor to the emerging epidemic is dementia. The Indian population is aging rapidly, with the proportion of older adults in India predicted to increase from 76 million to 301 million by 2051. Traumatic Brain Injury (TBI). It is estimated that 1 million persons are disabled due to TBI annually. Stroke. With incidence doubled, the incidence rate of stroke in India is currently estimated to be 145 per 100,000 people.

Our access to the most prominent Neuropsychiatry sites and Investigators ensures a large and diverse patient pool and leading lines of medical treatment. Using our internal databases and epidemiology intelligence we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients.

We ensure that neurological clinical trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download: NeuroPsychiatric Brochure
Excel Life Sciences (ELS) has significant experience in running and supporting clinical trials for oncology in India. In fact, ELS has one of the largest networks of investigative sites and investigators in India, including some of the country’s leading oncology investigators and centers.

Over 2.5 million adults suffer from Cancer related disease in India. In 2013, 1,230,000 new cases were diagnosed, and 700,000 people died of cancer related diseases.

Stomach cancer is the top killer for the population as a whole, breast cancer among women, and lung cancer among men. Tobacco related cancer account for nearly one third of all cancers in India, predominantly head and neck, lung, and esophageal cancers. India women most commonly suffer from cervical, uteri and breast cancer. The incidence of breast cancer in India is increasing, with an estimated 145,000 new cases diagnosed (2012). About 17% of the world’s breast cancer population are in India. Cancer incidence in India is estimated to increase from 90 per 100,000 population to 130-170 per 100,000 population by 2020. Currently, cancer treatment market in India is estimated at USD 1.7-2.0 billion, in 2015.

India, given extensive oncology infrastructure, is a base for many cancer clinical trials, including breast cancer clinical trials, ovarian cancer clinical trials, prostate cancer clinical trials, lung cancer clinical trials and colon cancer clinical trials. Using our databases of detailed site information, demographics and epidemiology data, we can quickly determine if India is the right fit for your study.

In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients. We have significant experience in the area of oncology and ensure that clinical trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download: Oncology Brochure 
Prevalence for ocular diseases in India is generally similar to global conditions. In some conditions such as vision impairment, the prevalence is significantly higher. Estimated number of people visually impaired in India is approximately 51 million or 18% of the worldwide 285 million.

As a developing country, India has many diseases and conditions in this therapeutic area. The prevalence of diseases leading to blindness in India is extremely high. There are approximately about 15 million blind people in India. The leading causes of blindness in India are Cataract (55%), Refractive errors (19%), Glaucoma (4%) and Corneal Pathology (7%). It is estimated that due to population growth and increased longevity, by 2020 there will be approximately 14 million blind people in India.

Other indications seen include Dry Eye, Anterior Uveitis and Necrotizing Retinosis. Yet other common forms of the diseases under ophthalmology are strabismus, amblyopia, congenital glaucoma, congenital cataracts and trauma.

Excel Life Sciences (ELS) has developed one of the most experienced and sophisticated networks of ophthalmology investigators and investigative sites in India. Each has deep access to a large and diverse patient pool and sees more than 300 new patients every month.

Using our databases of detailed site information, demographics and epidemiology data we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients. We have conducted a number of studies in the area of ophthalmology and we are confident that we can assist you with your next study.

We ensure that clinical trials in ophthalmology are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download: Ophthalmology Brochure
Excel Life Sciences (ELS) has significant experience in running and supporting clinical trials for orthopedic disorders and diseases in India. In fact, ELS has one of the largest networks of investigative sites and investigators in India, including some of the countries leading investigators and centers treating orthopedic conditions. In India, the science of orthopedics is quickly evolving. Today there are approximately 20,000 practitioners throughout the country and this number continues to increase. One of the most prevalent conditions in this therapeutic area is Arthritis where there are more than 150 million patients currently under treatment. Many top Orthopedics centers in India are reporting an average overall increase in out patients of 5% – 10% per year.

Investigative sites within the ELS network have the experience and infrastructure necessary to conduct global clinical trials requiring the highest levels of ethics, quality and performance. These institutions specialize in the latest techniques and treatments in the area of orthopedics including minimally invasive surgery, cartilage and bone transplantation, spine surgery and limb sparing surgery. They have deep access to a diverse treatment naive patient pool, with each seeing more than 100 new patients every month. Data from our sites suggests that between the years 2003 to 2006 the leading Investigators treated approximately 70,000 patients in this therapeutic area. Many patients are treatment naïve and non-transient. These factors typically result in shortened enrollment times.

Using sophisticated databases of detailed site information, demographics and epidemiology data we can quickly determine if India is the right fit for your study. In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients. We have significant experience in the area of orthopedics and we are confident that we can assist you with your next study. Contact our business development team today to learn more!

Download: Orthopedics Brochure  
Respiratory diseases impose a tremendous health burden on Indian patients. In India, as in other industrializing countries, rising pollution and changes in lifestyle contribute to increased levels of respiratory disease. One of the most prevalent respiratory diseases in India is Chronic Obstructive Pulmonary Disease (COPD). Estimates predicted that by 2016, about 5.9M people in urban areas 16.3M people in rural areas in India will suffer from COPD. Other major emerging health problems in the region are asthma, interstitial lung disease (ILD), pneumonia, tuberculosis (TB), respiratory allergies, occupational lung diseases and bronchial hypertension.

A recent study of 85,000 men and 84,500 women from 12 urban and 11 rural sites reported the prevalence of chronic bronchitis to be 3.49% (4.29% in males and 2.7% in females) in adults > 35 years. Other studies show that pulmonary fibrosis accounts for 15% of all cases seen by pulmonary physicians. Lastly, India has the highest rate of death due to respiratory diseases in the world, where respiratory cases rose by 5 million from 2012 alone.

Excel Life Sciences (ELS) has significant experience in running and supporting clinical trials for respiratory diseases in India. In fact, ELS has one of the largest networks of investigative sites and investigators in India, including some of the country’s leading investigators and centers treating respiratory diseases. Using our databases of detailed site information, demographics and epidemiology data we can quickly determine if India is the right fit for your study.

In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients. We have significant experience in the area of pulmonary / respiratory, and we are confident that we can assist you with your next study.

We ensure that respiratory clinical trials are conducted according to ICH - GCP guidelines and meet the highest standards of ethics and integrity.

Download: Pulmonary Brochure